The specialist drug development Company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases has announced a fundraise of £1.02m at 0.6p. This included £0.3m via the PrimaryBid platform whereby retail investors were given the opportunity to participate on the same terms as institutional investors.
03 Jun 2020
£1.02m raised to progress proprietary TYK2/JAK1 programmes
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
£1.02m raised to progress proprietary TYK2/JAK1 programmes
Sareum Holdings plc (SAR:LON) | 29.5 1.8 26.9% | Mkt Cap: 30.0m
- Published:
03 Jun 2020 -
Author:
Derren Nathan -
Pages:
8
The specialist drug development Company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases has announced a fundraise of £1.02m at 0.6p. This included £0.3m via the PrimaryBid platform whereby retail investors were given the opportunity to participate on the same terms as institutional investors.